Back

Effects of recombinant GDF15 pretreatment on mitochondrial damage and cytotoxicity induced by doxorubicin in human stem cell-derived cardiomyocytes

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in basic science (2) Cardiomyopathies HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Associate Professor Erik Fung

Hong Kong University of Science and Technology, Hong Kong (China)

5 More presentations in this session

Presentation thumbnail
Evaluating the potential for SPAR to detect changes in ECGs with time matched disease progression in ATTR-Cardiac Myopathy a proof of concept study
Mr J. Rickard (London, GB)
Abstract Slides Video
Presentation thumbnail
Exploring nucleotide metabolism and nicotinamide riboside effects in hypertrophic cardiomyopathy
Ms K. Stawarska (Gdansk, PL)
Abstract Slides Video
Presentation thumbnail
Influence of subclinical hypothyroidism on systolic and diastolic cardiac function post-acute myocardial infarction: a prospective cohort study
Doctor N. Kurup (Gateshead, GB)
Abstract Slides Video
Presentation thumbnail
Connexin-43 deficiency in subsarcolemmal mitochondria of cardiomyocytes of dogs with chronic heart failure
Professor H. Sabbah (Detroit, US)
Abstract Slides Video
Presentation thumbnail
Pathophysiological and therapeutic implications of urocortin-2 in heart failure with preserved ejection fraction
Doctor R. Adao (Madrid, ES)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in basic science (2)

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55/YY1/sST2 signaling axis
thumbnail
Congress Presentation
Deciphering doxorubicin-induced cardiotoxicity:insights at single-cell resolution
thumbnail
Congress Presentation
Plasma levels of human growth differentiation factor 15 (GDF-15) and their effect of alirocumab on major adverse cardiovascular events and all-cause death after acute coronary syndrome

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources